WO2019129761A1 - Compositions et procédés pour soins de l'oeil et du nez - Google Patents

Compositions et procédés pour soins de l'oeil et du nez Download PDF

Info

Publication number
WO2019129761A1
WO2019129761A1 PCT/EP2018/086832 EP2018086832W WO2019129761A1 WO 2019129761 A1 WO2019129761 A1 WO 2019129761A1 EP 2018086832 W EP2018086832 W EP 2018086832W WO 2019129761 A1 WO2019129761 A1 WO 2019129761A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
fatty acids
multilamellar vesicles
spray
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/086832
Other languages
English (en)
Inventor
Floris Koumans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ursapharm Arzneimittel GmbH
Original Assignee
Ursapharm Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursapharm Arzneimittel GmbH filed Critical Ursapharm Arzneimittel GmbH
Publication of WO2019129761A1 publication Critical patent/WO2019129761A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Definitions

  • the present invention relates to multilamellar vesicles and to the use of these vesicles in ocular and nasal care.
  • Lecithin-based liposomes have been widely used for transdermal application of pharmaceutically active ingredients, such as alkaloids, contraceptives, insulin and salicylic acid derivatives.
  • pharmaceutically active ingredients such as alkaloids, contraceptives, insulin and salicylic acid derivatives.
  • the cosmetic industry has applied the findings of the pharmaceutical industry, and used it for topical delivery of cosmetically active substances, such as moisturisers, botanicals, vitamins and ceramides.
  • the size of the liposomes may vary from 20 nm to 1000 nm. Because of their size they are able to pass the stratum corneum of the skin and deliver the active compound. In practice this can be done until the first subcutaneous membrane is reached.
  • W094/01089 discloses an eye spray comprising lecithin-based liposomes.
  • lecithin -based liposomes One drawback of lecithin -based liposomes is that the presence of other surface active agents, such as emulsifiers, solubilisers or wash-active ingredients, will destabilise the liposome, since the additional surface active agents will impart in the liposomal structures. Consequently liposomes cannot be applied in traditional emulsions and wash-active preparations.
  • surface active agents such as emulsifiers, solubilisers or wash-active ingredients
  • lecithin-based liposomes are usually characterised by a relatively low degree of loading. Loading capacity may be high enough for pharmaceutical preparations, but is in most cases insufficient for cosmetic ingredients.
  • lecithin -based liposomes Another drawback of lecithin -based liposomes is the fact that the molecule needs to be unsaturated to produce liposomes. Theoretically it is possible to prepare lecithin-based liposomes on the basis of hydrogenated phosphatidylcholine, but it is difficult and does not allow for targeted controlled release. In practice therefore unsaturated phosphatidylcholine is required to prepare liposomes that enable targeted controlled release. Unsaturation, easily leads to peroxide formation and the formation of malondialdehyde, the typical odour of rancid oils and fats. This is a very sincere limitation for using lecithin-based liposomes.
  • lecithin-based liposomes Another drawback of lecithin-based liposomes is their size, frequently in the range of 500-800 nm. This does not allow for sterile filtration to avoid contamination with micro organisms. Therefore, preservatives need to be added to lecithin-based liposome
  • the present invention relates to a multilamellar vesicle comprising neutralised hydrogenated polymerised fatty acids, wherein the fatty acids are obtained from a feedstock comprising C18 unsaturated fatty acids.
  • the multilamellar vesicles according to the invention have several advantages.
  • One advantage is their stability. Unlike lecithin-based liposomes, the multilamellar vesicles according to the invention are insensitive to surface agents and therefore ideal for a wide variety of formulations.
  • the multilamellar vesicles according to the invention may be applied in emulsions and wash-active products.
  • multilamellar vesicles according to the invention may be fully hydrogenated and thereby become insensitive to oxidation. This avoids the problem of the formation of peroxide and malondialdehyde, leading to the typical odour of rancid oils and fats.
  • vesicles are smaller than most lecithin-based liposomes, which frequently have a size in the range of 500-800 nm.
  • the multilamellar vesicles according to the invention have a flexible width of 100 to 400 nm, which allows them to pass a 200 nanometer filter or opening. Therefore, use of the vesicles according to the invention enables the production of preservative-free spray formulations, since products according to the invention allow for sterile filtration.
  • a spray comprising multilamellar vesicles according to the invention is sterilized on leaving the spray bottle nozzle which is provided with a 200 nm opening.
  • Another advantage is the relatively simple and uncomplicated production process of the multilamellar vesicles according to the invention.
  • the process for preparing the multilamellar vesicles involves neutralization and addition of energy. No spacers or linker molecules are required to obtain the vesicles, making the production process more economical and practical.
  • lecithin-based liposomes refers to phospholipid-based liposomes wherein the phospholipid comprises a phosphatidylcholine or phosphatidylcholine- derivative in the polar head group.
  • compositions may be prepared using the multilamellar vesicles according to the invention.
  • the vesicles are prepared from hydrogenated polymerised unsaturated fatty acids.
  • the unsaturated fatty acids for polymerization may be obtained from any feedstock comprising mono- unsaturated or poly-unsaturated fatty acids. Suitable examples include linseed oil, olive oil, palm oil and rape seed oil. However, since the application of the product is in personal care, medical devices or pharmaceutical products, preferably soy-based feedstock is used. In one embodiment, soy bean oil comprising a mixture of mono-unsaturated and poly unsaturated fatty acids is used as the feedstock.
  • the unsaturated fatty acids are ethylenically unsaturated C12-C30 fatty acids. In another embodiment, the unsaturated fatty acids are ethylenically unsaturated 18 fatty acids, such as oleic acid and linoleic acid.
  • polymerization of unsaturated fatty acids include acid or alkaline clays and strong Lewis acids.
  • a suitable example of a strong Lewis acid is lithium carbonate.
  • the catalyst may be positioned on a carrier, for example on a silica support.
  • the polymerized fatty acid product is prepared by polymerisation of soy bean feedstock at a temperature in the range of 200 to 300 DEG C using lithium carbonate on a silica support as a catalyst.
  • the polymerised product comprises a mixture of polymerized fatty acids, which for example may be acyclic, monocyclic, bicyclic or aromatic.
  • the mixture may comprise isomers, including structural isomers, such as positional isomers, and stereoisomers, such as cis-trans isomers.
  • Dimerised fatty acids, 36 carbon dibasic acids are the major component in the mixture, but monomers, trimers, higher fatty acid polymers or isostearic acids may also be present after
  • the ratio of these different polymers will depend on the feedstock used.
  • the mixture comprises at least 95% w/w or at least 98% w/w dimer acids, C36 dimer acids, preferably from dimerized C18 soy fatty acids.
  • the polymerised product is hydrogenated to remove all or part of the unsaturated bonds. In one embodiment, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the unsaturated bonds are removed. Hydrogenation may be carried out using methods known in the art, typically by using hydrogen at a temperature in the range of 200 DEG C to 400 DEG C at elevated pressure in the presence of a catalyst, for example as described in GB 999 732 resulting in a viscous and virtually colourless liquid at ambient temperature.
  • Polymerised fatty acids or hydrogenated polymerised fatty acids may be obtained commercially. Any commercially obtainable mixture of (hydrogenated) polymerized unsaturated fatty acids which contains polymers of C12-C30 fatty acids may be used.
  • a hydrogenated polymerised fatty acid composition comprises at least 95% w/w or at least 98% w/w hydrogenated dimer acids, hydrogenated C36 dimer acids, preferably from dimerised C18 soy fatty acids, is used.
  • a hydrogenated polymerized fatty acid composition is used which has an acid value in the range of 194-198 (mg KOH/g), an iodine value below 15 (g/100 g), preferably 10 (g/100 g) or less or more preferably 0.5 (g/100 g) or less and a dicarboxylic acid content of at least 95%w/w, preferably more than 98%w/w.
  • a suitable example of a commercially available hydrogenised polymerized fatty acid mixture is Pripol 1009 (Uniqema Nederland BV, Gouda, The Netherlands).
  • the different products in the polymerization product may be separated from each other.
  • dimers are separated from monomers, trimer and higher polymers which are present in the mixture after polymerization. Separation may be performed using methods known in the art, for example methods including distillation. In another embodiment, there is no separation of the polymerized products in the mixture before or after
  • the hydrogenated polymerised fatty acid mixture itself does not form vesicles.
  • the vesicles are only obtained after neutralization of the hydrogenated polymerised fatty acids and addition of energy, preferably mechanical energy.
  • a method for preparing a composition comprising multilamellar vesicles according to the invention is another aspect of the present invention.
  • a method for preparing a composition comprising multilamellar vesicles according to the invention comprises:
  • composition comprising hydrogenated polymerised fatty acids
  • the hydrogenated polymerised fatty acids are neutralized with a base.
  • bases for neutralization include 2-amino-ethanol (MEA), triethanolamine (TEA), 2-amino-2-methylpropan-l-ol (AMP), 2-amino-2-methyl-l, 3-propanediol (AMPD) and 2-amino- 2-hydroxymethyl-propane-l,3- diol (Tris).
  • Tris is the preferred neutralising agent because Tris does not lead to irritation of the mucosa of the eye or the nose.
  • the ratio hydrogenated polymerised fatty acids: neutralisation agent is in the range from 2.0: 1 up to 2.3:1. In another embodiment, the ratio is 2.22:1.
  • the neutralised hydrogenated polymerised fatty acids may be present in salt form, acid form or anion form. In one embodiment, the neutralised hydrogenated polymerised fatty acids are present in salt form.
  • the solvent is preferably a diol compound, such as 1,3-propanediol (1, 3-dihydroxypropane), 1,3 propylene glycol, 1,2 propylene glycol, glycerol (1,2,3-trihydroxypropane), trimethylolpropane, dimethyl isosorbide or 2-methyl-l,3- propylene glycol.
  • 1,3-propanediol is used as the solvent, since it does not cause skin or eye irritation, nor does it lead to sensitisation.
  • Suitable concentrations of the solvent are from 1% to 60%, from 20% to 50% or from 40% to 55% by weight of composition.
  • Energy is required to obtain the multilamellar vesicles.
  • Energy may be added by methods known in the art, such as by homogenization, high speed mixing or sonication.
  • neutralised hydrogenated polymerized fatty acids are converted to multilamellar vesicles by high speed mixing for a period of 10 to 60 minutes at a speed of 7000 to 10 000 rpm, for example for a period of 20 to 40 minutes at 8000 rpm.
  • neutralised hydrogenated polymerized fatty acids are converted to multilamellar vesicles by sonication.
  • multilamellar vesicles comprising multiple bilayers, such as two, three or more, concentrically stacked one upon each other, like the layers of an onion, are formed.
  • multilamellar vesicles according to the invention comprise at least two, at least three, at least four or at least five bilayers, for example 2-12 bilayers, 4-12 or 5-8 bilayers.
  • the multilamellar vesicles comprising dehydrogenated fatty acids may be applied as such or may encapsulate other components.
  • Suitable examples of components which may be encapsulated include drug molecules, such as anti-inflammatory compounds or nursing and maintaining compounds, including anti-inflammatory agents, anti-oxidants, anti-microbial agents, lipids, vitamins and plant extracts.
  • drugs molecules such as anti-inflammatory compounds or nursing and maintaining compounds, including anti-inflammatory agents, anti-oxidants, anti-microbial agents, lipids, vitamins and plant extracts.
  • carbohydrates or carbohydrate derivatives, such as monosaccharide, sugars and polysaccharides, or derivatives thereof are encapsulated.
  • Suitable examples include a-glucanes, b-glucanes, N-acetylglucosamine, sialic acid, glycosaminoglycans polysaccharides and anti-microbial polysaccharides derivable from Aloe vera. Both hydrophilic and lipophilic components may be encapsulated.
  • the encapsulated compound is a sulfated glycosaminoglycan, preferably selected from the group consisting of chondroitin sulfates, keratan sulfate, chitin, hyaluronic acid and heparin, or salts or derivatives of these components.
  • hyaluronic acid is encapsulated.
  • Hyaluronic acid is preferably used in the form of the sodium salt, i.e. sodium hyaluronate.
  • Preferred hyaluronic compounds have a molecular weight of at least 10 kDa and at most 100,000 kDa. In one embodiment, the molecular weight of the hyaluronic compound is 2,000 kDa.
  • the encapsulated compound is used at an effective level.
  • the amount of encapsulated compound is from 0.01% to 10%, more preferably from 0.1% to 4%, most preferably 0.2 tol.5% by weight of the composition comprising the multilamellar vesicles.
  • the active compound is added before addition of energy.
  • active compound the same or another, is also added after the addition of energy.
  • the active is both encapsulated and non-encapsulated. This allows for both immediate release and controlled release of active from the multilamellar vesicle according to the invention. Therefore the beneficial effect of the active component may be immediate, for example within 5-10 seconds, and may be maintained for at least two to four hours due to the controlled release.
  • multilamellar vesicles may be confirmed by examination by means known in the art, for example by microscopy, such as light or electron microscopy.
  • multilamellar vesicles are detected by freeze fracture electron microscopy.
  • Multilamellar vesicles may be distinguished from micelles, which comprise a monolayer of surfactant material, while multilamellar vesicles comprise concentric bilayers. Concentric bi layers can easily be detected using the microscope and polarised light.
  • the multilamellar vesicles according to the invention are similar to liposomes, because both comprise several bilayers surrounding an aqueous core.
  • the multilamellar vesicles according to the invention comprise bilayers of neutralised hydrogenated polymerized fatty acids.
  • Multiple bilayers, such as two, three or more bilayers, are concentrically stacked one upon each other, like the layers of an onion, to form the multilamellar vesicles according to the invention.
  • the bilayers form the walls of the multilamellar vesicle and comprise neutralised hydrogenated polymerized fatty acids as the wall-forming material.
  • the multilamellar vesicles according to the invention offer a longer term depot of wetting compounds.
  • the Sauter mean diameter of the vesicles is in the range from 100 nm up to 400 nm, such as from 100 nm up to 350 nm, from 110 nm up to 250 or from 110 nm up to 200 nm, as determined by a particle sizer machine from AccuSizer 780 AD, Particle Sizing Systems, Santa Barbara, USA, equipped with an auto-dilution system.
  • the present invention relates to a composition comprising multilamellar vesicles according to the invention.
  • the composition comprises multilamellar vesicles, which vesicles comprise bilayers of neutralised hydrogenated polymerised fatty acids, whereby the unsaturated fatty acids were obtained from soy feedstock.
  • the composition is a milky white, non-transparent, odourless aqueous dispersion of multilamellar vesicles according to the invention.
  • the hydrogenated polymerised fatty acids may constitute from 0.01 to 20%, from 0.01 to 10% or from 0.10 to 5% by weight of the composition.
  • the composition comprises from 0.01 to 20% hydrogenated polymerised fatty acids and 0.30% of an active, such as sodium
  • hyaluronate by weight of the composition.
  • the composition comprises 50.200% demineralised water, 48.775% 1,3-propandiol, 0.500% hydrogenated polymerised fatty acids, 0.300% sodium hyaluronate and 0.225% tromethamine by weight of the composition.
  • the pH of the composition is or is adjusted to a pH in the range of pH 7.0 to pH 7.6, preferably in the range of pH 7.2 to pH 7.6. In one embodiment, the pH of the composition is 7.4. This allows for the application of the composition in personal care, medical devices or pharmaceutical products.
  • the viscosity of the composition is in the range of 300 to 500 mPas, determined at 19- 20 degrees C using using a Viscometer & Model Brookfield DV-II+ Programmable at spindle 2.
  • the osmolarity of the composition is may be in the range of 200 to 1500 mOsmol/kg, such as 200 to 1400 mOsmol/kg or 600 to 1400 mOsmol/kg . In one preferred embodiment, the osmolarity is in the range of 200 to 400 mOsmol/kg, for example in the range of 275 to 300 mOsmol/kg.
  • the density of the composition may be about 1.0105 g/cubic cm.
  • Excipients or additives such as buffers, stabilisers or thickeners may be added to the composition, as long as care is taken to maintain a pH in the range of pH 7.0 to pH 7.6, preferably in the range of pH 7.2 to pH 7.6.
  • the composition may be perfumed.
  • the multilamellar vesicles according to the invention are resistant to and remain stable in the presence of perfume compounds which are often excellent solvents.
  • the composition is not perfumed.
  • the composition may be a non-sterile or sterile composition.
  • the composition preferably comprises max.10 CFU/g and pathogens and spores are absent.
  • the compositions according to the invention allow for in use sterilisation by filtration, due to the size of the multilamellar vesicles. Therefore, there is no need to add preservatives and preservatives such as chlorohexidine, organic acids, such as benzoic acid, formic acid, lactic acid, levulinic acid and sorbic acid or parabens, such as propyl paraben, butyl paraben, are preferably not added.
  • a preservative which is not necessary because the composition may be sterilized by filtration, preferably a non-ionic preservative which is compatible with a pH in the range of pH 7.0 to pH 7.6 is used.
  • a sterile composition without preservatives, and a method for obtaining such a composition, is also part of the invention.
  • the composition is used in personal care, as a medical device or in a pharmaceutical product, for example as a moisturizer, as a carrier or in a sun screen.
  • the composition is preferably used in applications in the range of pH 7.0 to 7.6. Therefore, the composition may advantageously be applied to the eye or nose, for example to the ocular or nasal mucosa.
  • the composition is for use in a method for the prevention or treatment of ocular or nasal conditions.
  • the composition is for use in a method for ocular or nasal care.
  • the composition is for application to dry eyes or dry nose.
  • the composition according to the invention may be used to alleviate, treat or prevent dry eye problems such as in dry eye syndrome.
  • the dry eye problem may be light, moderate or severe.
  • Use of the composition according to the invention may lead to improvements in eye problems, for example to improvement in subjective comfort (more), eye redness (less), eye irritation or burning (less), tear film deficiencies (corrected) or tear break-up time (TBUT, minimally 15 seconds).
  • the composition may be applied to the closed eye lid (spray) or to the inner side of the lower eye lid (drops). The drops may then be introduced into the eye by movement of the eye lid.
  • the composition may advantageously be used by contact lens wearers, people with allergy and people over 40, which groups more frequently than other people experience dry eye problems or problems of burning or itching eyes.
  • the composition according to the invention may be used to alleviate, treat or prevent dry nose problems.
  • the dry nose problem may be light, moderate or severe.
  • Use of the composition according to the invention may lead to improvement in subjective comfort (more) or to a more moisturised nasal mucosa.
  • the nasal spray may for example be formulated into a spray in a pump bottle or in a pressurized bottle.
  • composition may advantageously be used by people with allergy, people with a cold, people on certain medication or with certain medical conditions and people who smoke. These groups more frequently than other people experience dry nose problems.
  • composition may be formulated into a suitable application form such as spray, lotion, gel, drops, nasal plug or wipes, which may be applied in any convenient way, such as by spray bottle, pump bottle, pressurized bottle, sponge, bandage or dosing system with pipette.
  • a suitable application form such as spray, lotion, gel, drops, nasal plug or wipes, which may be applied in any convenient way, such as by spray bottle, pump bottle, pressurized bottle, sponge, bandage or dosing system with pipette.
  • the dosing system may be a monodose system or multidose systems.
  • a composition of multilamellar vesicles loaded with 0.3% hyaluronate by weight of the vesicles is used in an eye spray to reach a final concentration of hyaluronate in the range of 0.015% to 0.040%, preferably in the range of 0.020% to 0.030% by weight of the spray composition.
  • a composition of multilamellar vesicles loaded with 0.3% hyaluronate by weigth of the vesicles are used in an eye drop composition to reach a final concentration of hyaluronate in the range of 0.08% to 0.2% by weight of the eye drop composition.
  • the composition is formulated into a spray, for example an eye spray or a nasal spray.
  • a spray for example an eye spray or a nasal spray.
  • two puffs or three puffs are applied from about 10 cm in the direction of the closed upper eyelid, immediately followed by forced blinking 3 to 5 times.
  • the eye spray reliefs dryness and redness of the eye, which effect is immediate and maintained for at least four hours or at least six hours.
  • the tip is inserted careful and gently in one nostril, while the other nostril is closed with a finger.
  • the head is preferably held upright and before the spray is used nasal passages are preferably cleared by gently blowing of the nose.
  • the bottle is squeezed while slowly breathing in through the nose. Then the bottle is removed and the spray is applied to the other nostril. The effect is immediate and last for several hours.
  • the multilamellar vesicles in the composition may encapsulate an active compound, as indicated above.
  • the composition comprises an encapsulated active and non-encapsulated active. This allows for a combination of direct release and controlled release of the active.
  • an eye spray is applied comprising multilamellar vesicles comprising both encapsulated and non-encapsulated hyaluronic acid.
  • hyaluronic acid is preferably used in a concentration of at least 0.015% and not more than 0.03% by weight of the composition.
  • the formulation may be a non-sterile or sterile formulation.
  • the formulation is a sterile formulation.
  • a suitable method for preparing a sterile formulation is by sterile filtration of a composition according to the invention.
  • the composition according to the invention is sterilised by filtration through a 200 nanometer filter or opening.
  • the filter or opening may be part of a spray bottle.
  • the composition is a spray formulation in a spray bottle with spray nozzle and is sterilized while it passes the filter or opening in the spray nozzle.
  • Embodiments and preferred embodiments mentioned for the method of preparing the composition comprising multilamellar vesicles may also be applied to the vesicles, to the composition and to the use of the composition, and vice versa.
  • Particle size and particle size distribution was determined using a particle sizer machine (AccuSizer 780 AD, Particle Sizing Systems, Santa Barbara, USA), equipped with an auto-dilution system.
  • Viscosity was determined at 19-20 degrees C using using a Viscometer & Model
  • Particle size and particle size distribution of the dispersion prepared in Example 1 were determined using a particle sizer machine (AccuSizer 780 AD, Particle Sizing Systems, Santa Barbara, USA), equipped with an auto-dilution system, before and after sterilization for 15 minutes at 115 deg C and 1.5 bar pressure,. The results obtained are shown in Table 1. The measurements show a bimodal Gauss curve. Table 1
  • the residue value was 0%, which means that there are no aggregates larger than 500 nm present, which would be indicative of aggregates of insufficiently dissolved sodium
  • the vesicles have a flexible width with a compression factor of 2.0 at 100 kPa. Therefore, vesicles of up to 400 nm will still be able to pass through a 200 nm opening.
  • Example 1 The composition prepared in Example 1 was used in a spray formulation in a concentration of 10%.
  • Spray containers with a 200 nanometer filter integrated in the spray nozzle were filled with the spray formulation and tested on individuals suffering from moderate dry eye syndrome.
  • Two puffs were applied from about 10 cm in the direction of the closed upper eyelid, immediately followed by forced blinking 3 to 5 times.
  • Example 4 physical- chemical parameters before and after filtration
  • a hydrogenated fatty acid vesicle composition was prepared as described in Example 1.
  • the composition was adjusted to different pH values using citric acid. These pH values represent pH values of the different production steps or pH values of different physiological conditions in the body.
  • the composition was analysed for physical- chemical parameter before and after filtration using European Pharmacopoeia standard methods as indicated.
  • the composition was filtered through a 32mm Syringe Filter with 0.8/0.2 pm polyethersulfone Supor ® Membran (Pall Life Sciences, Ml, USA). Appearance, pH and osmolarity were measured according to European pharmacopeia standard methods. Odour was determined organoleptically. Results are presented in Table 2.
  • the pH, a critical physical-chemical parameter, was not affected by filtration.
  • the solution remained a transparent -opaque odourless and colourless solution.
  • a multilamellar vesicle composition according to the invention was prepared according to Example 1, and additionally contained 5% w/w betaine and 30% w/w Aloe vera high molecular negatively charged polysaccharides.
  • 5% w/w betaine and 30% w/w Aloe vera high molecular negatively charged polysaccharides were investigated.
  • the product was treated with 10ml air via a 32mm Syringe Filter with 0.8/0.2 pm polyethersulfone Supor ® Membran (Pall Life Sciences, Ml, USA) and a cannula and stored at 25°C/60%rH or 40°C/75%rH for 13 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition comprenant des vésicules multilamellaires provenant d'acides gras polymérisés hydrogénés neutralisés. Les acides gras polymérisés hydrogénés sont obtenus à partir d'une charge comprenant des acides gras insaturés en C18. Les vésicules multilamellaires sont excellentes pour des soins de l'oeil ou du nez.
PCT/EP2018/086832 2017-12-27 2018-12-22 Compositions et procédés pour soins de l'oeil et du nez Ceased WO2019129761A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17210662 2017-12-27
EP17210662.7 2017-12-27

Publications (1)

Publication Number Publication Date
WO2019129761A1 true WO2019129761A1 (fr) 2019-07-04

Family

ID=60813672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/086832 Ceased WO2019129761A1 (fr) 2017-12-27 2018-12-22 Compositions et procédés pour soins de l'oeil et du nez

Country Status (1)

Country Link
WO (1) WO2019129761A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2955121A (en) 1959-08-24 1960-10-04 Emery Industries Inc Polymerization of unsaturated fatty acids
GB999732A (en) 1962-03-01 1965-07-28 Gen Mills Inc Decolourising polymeric fatty acids
US3632822A (en) 1969-02-04 1972-01-04 Arizona Chem Polymerization of unsaturated fatty acids
DE3327645A1 (de) * 1983-07-30 1985-02-07 Henkel KGaA, 4000 Düsseldorf Vesikel aus dimersaeure-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung
US4776983A (en) 1985-03-22 1988-10-11 Union Camp Corporation Polymerization of fatty acids
WO1994001089A1 (fr) 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomes, procede concernant leur fabrication, et leur utilisation dans la fabrication d'un medicament
WO2000037053A1 (fr) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Systeme de liberation de medicament a grosses molecules, dans lequel des amphiphiles en aerosol, imitant une membrane, sont utilises
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2002053873A1 (fr) * 2000-12-30 2002-07-11 Halliburton Energy Services, Inc. Nouveaux composes et procede permettant de generer une membrane hautement efficace dans des fluides de forage aqueux
WO2003000190A2 (fr) * 2001-06-25 2003-01-03 Depuy Encapsulation liposomale de glycosaminoglycanes pour le traitement d'articulations arthrosees
WO2012021107A2 (fr) * 2010-08-12 2012-02-16 Nanyang Technological University Formulation de liposomes pour l'administration d'un médicament dans l'œil
WO2016139322A1 (fr) * 2015-03-03 2016-09-09 Spheritech Ltd Microparticules

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2955121A (en) 1959-08-24 1960-10-04 Emery Industries Inc Polymerization of unsaturated fatty acids
GB999732A (en) 1962-03-01 1965-07-28 Gen Mills Inc Decolourising polymeric fatty acids
US3632822A (en) 1969-02-04 1972-01-04 Arizona Chem Polymerization of unsaturated fatty acids
DE3327645A1 (de) * 1983-07-30 1985-02-07 Henkel KGaA, 4000 Düsseldorf Vesikel aus dimersaeure-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung
US4776983A (en) 1985-03-22 1988-10-11 Union Camp Corporation Polymerization of fatty acids
WO1994001089A1 (fr) 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomes, procede concernant leur fabrication, et leur utilisation dans la fabrication d'un medicament
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2000037053A1 (fr) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Systeme de liberation de medicament a grosses molecules, dans lequel des amphiphiles en aerosol, imitant une membrane, sont utilises
WO2002053873A1 (fr) * 2000-12-30 2002-07-11 Halliburton Energy Services, Inc. Nouveaux composes et procede permettant de generer une membrane hautement efficace dans des fluides de forage aqueux
WO2003000190A2 (fr) * 2001-06-25 2003-01-03 Depuy Encapsulation liposomale de glycosaminoglycanes pour le traitement d'articulations arthrosees
WO2012021107A2 (fr) * 2010-08-12 2012-02-16 Nanyang Technological University Formulation de liposomes pour l'administration d'un médicament dans l'œil
WO2016139322A1 (fr) * 2015-03-03 2016-09-09 Spheritech Ltd Microparticules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUHRHOP J-H ET AL: "VESICLES FROM DIMER ACID AND ITS DERIVATIVES", LANGMUIR, vol. 1, 1985, AMERICAN CHEMICAL SOCIETY, US, pages 387 - 390, XP001091272, ISSN: 0743-7463, DOI: 10.1021/LA00063A022 *
PINTO-FRAGA J ET AL: "Efficacy and safety of 0.2% hyaluronic acid in the management of dry eye disease", EYE AND CONTACT LENS, vol. 43, no. 1, January 2017 (2017-01-01), LIPPINCOTT WILLIAMS AND WILKINS USA, pages 57 - 63, XP055495749, ISSN: 1542-2321 *

Similar Documents

Publication Publication Date Title
KR100489701B1 (ko) 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
KR102555803B1 (ko) 하이드로젤 캡슐, 이의 제조방법 및 이를 포함하는 화장료 조성물
CN101511340B (zh) 使用酯化卵磷脂的纳米脂质体、其制备方法和含有其的用于预防或治疗皮肤疾病的组合物
Gupta et al. Glycerosomes: advanced liposomal drug delivery system
US10307349B2 (en) Apparatus and method for preparing cosmeceutical ingredients containing epi-dermal delivery mechanisms
EA021149B1 (ru) Косметические или дерматологические пенные составы, их применение и способы получения
EP2155148A2 (fr) Formulations de mousses exemptes d'agent tensio-actif
KR102181475B1 (ko) 난용성 성분 안정화용 조성물 및 이를 포함하는 화장료 조성물
CN102327199B (zh) 包含具有双壳结构的纳米结构体的化妆品成分
JP2003533491A (ja) 薬学的及び／又は美容的組成物
CN108498368A (zh) 用于增强皮肤状况改善物质的皮肤渗透性的化妆品组合物
KR20160065328A (ko) 리포좀을 포함하는 화장료 조성물
US20250057767A1 (en) Composition comprising hybrid exosome
KR102648442B1 (ko) 향상된 흡수력을 갖는 경피 흡수 마이셀 및 이를 포함하는 경피 흡수 조성물
WO2018130390A1 (fr) Introduction de substances actives faiblement solubles et/ou non solubles dans l'eau au moyen de nanoparticules/vésicules à base de lipides dans un reseau tridimensionnel hydrophile de cellulose
KR102248067B1 (ko) 화장료 조성물
EP3666259A1 (fr) Compositions aqueuses capables de mousser a base de biopolymeres avec une distribution de cellulures memoire de gas flexible selon son usage
CN115702868A (zh) 包含难溶性成分得到稳定化的纳米囊泡的水包油型化妆料组合物
US20070104774A1 (en) Method for preparing phytosphingosine liposome composition
KR20150072040A (ko) 디팔미토하이드록시프롤린을 포함하는 나노 전달체 함유 화장료 조성물
WO2019129761A1 (fr) Compositions et procédés pour soins de l'oeil et du nez
KR20200070091A (ko) 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법
JP6150010B2 (ja) 皮膚外用剤及び皮膚刺激低減剤
WO2007012625A1 (fr) Preparation ophtalmologique sterile, multiphase, exempte d'emulsifiant, coulant en gouttes
CN114177116B (zh) 一种水杨酸纳米组合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18827124

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18827124

Country of ref document: EP

Kind code of ref document: A1